Junia V Melo
Overview
Explore the profile of Junia V Melo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohty M, Melo J
Clin Hematol Int
. 2025 Feb;
7(1):10-13.
PMID: 39911608
High-quality peer review is a cornerstone of credible and impactful scientific and medical publishing. This manuscript provides a comprehensive overview of the best practices, responsibilities, and evaluation criteria for peer...
2.
3.
4.
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, et al.
Nat Commun
. 2019 Oct;
10(1):4741.
PMID: 31628323
Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in B-ALL. Loss of CDK8 in leukemia mouse...
5.
Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, et al.
Neoplasia
. 2018 May;
20(6):632-642.
PMID: 29772458
Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about...
6.
Mitchell R, Hopcroft L, Baquero P, Allan E, Hewit K, James D, et al.
J Natl Cancer Inst
. 2017 Nov;
110(5):467-478.
PMID: 29165716
Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a...
7.
Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr W, et al.
Oncotarget
. 2017 Oct;
8(40):67709-67722.
PMID: 28978065
Acute lymphoblastic leukemia (ALL) is characterized by leukemic expansion of lymphoid blasts in hematopoietic tissues. Despite improved therapy only a subset of patients can be cured. Therefore, current research is...
8.
de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone R, et al.
Leuk Res
. 2015 Sep;
PMID: 26413753
Current treatment options as well as clinical efficacy are limited for chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In response to the pressing...
9.
Loi T, Dai P, Carlin S, Melo J, Ma D
Leuk Lymphoma
. 2015 Apr;
57(2):411-418.
PMID: 25904380
Durable responses to imatinib monotherapy are rarely seen in aggressive forms of Philadelphia chromosome positive (Ph+) leukemias. To investigate the possible cause of treatment failure we examined the role of...
10.
Chereda B, Melo J
Ann Hematol
. 2015 Mar;
94 Suppl 2:S107-21.
PMID: 25814077
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t(9;22) chromosomal translocation, resulting in the formation...